Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | L3MBTL3 | Q96JM7 | 8/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 8/20 | 0.42 |
| ▸ | MBTD1 | Q05BQ5 | 2/20 | 0.36 |
| ▸ | NCF1 | P14598 | 1/20 | 0.36 |
| ▸ | HTR6 | P50406 | 1/20 | 0.35 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.34 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL358559 | 1.00 | ALDH1A1 (0.44) | ALDH1A1L3MBTL3L3MBTL1MBTD1NCF1 | |
| SCHEMBL8272496 | 1.00 | ALDH1A1 (0.44) | ALDH1A1L3MBTL3L3MBTL1MBTD1NCF1 | |
| SCHEMBL8438291 | 0.98 | ALDH1A1 (0.43) | ALDH1A1L3MBTL3L3MBTL1MBTD1CYP2D6 | |
| SCHEMBL8439289 | 0.98 | ALDH1A1 (0.43) | ALDH1A1L3MBTL3L3MBTL1MBTD1CYP2D6 | |
| SCHEMBL8374383 | 0.98 | ALDH1A1 (0.43) | ALDH1A1L3MBTL3L3MBTL1MBTD1CYP2D6 | |
| SCHEMBL8272489 | 0.98 | ALDH1A1 (0.43) | ALDH1A1L3MBTL3L3MBTL1MBTD1CYP2D6 | |
| SCHEMBL8272492 | 0.98 | ALDH1A1 (0.43) | ALDH1A1L3MBTL3L3MBTL1MBTD1CYP2D6 | |
| SCHEMBL23588990 | 0.95 | ALDH1A1 (0.44) | ALDH1A1L3MBTL3L3MBTL1MBTD1NCF1 | |
| SCHEMBL25853905 | 0.95 | ALDH1A1 (0.44) | ALDH1A1L3MBTL3L3MBTL1MBTD1NCF1 | |
| SCHEMBL15600757 | 0.95 | ALDH1A1 (0.44) | ALDH1A1L3MBTL3L3MBTL1MBTD1NCF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230117631-A1 | HPK1 ANTAGONISTS AND USES THEREOF | Nimbus Saturn, Inc. | 2023-04-20 | — | — | US | disclosed |
| WO-2021129820-A1 | SPIRO RING-CONTAINING QUINAZOLINE COMPOUND | 微境生物医药科技(上海)有限公司 | 2021-07-01 | — | — | WO | disclosed |
| US-10208067-B2 | Compounds for treating spinal muscular atrophy | HOFFMANN-LA ROCHE INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-20180194781-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | HOFFMANN-LA ROCHE INC. (US) | 2018-07-12 | — | — | US | disclosed |
| WO-2016184832-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | F. HOFFMANN-LA ROCHE AG (CH) | 2016-11-24 | — | — | WO | disclosed |
| WO-2015197503-A1 | IMIDAZO[1,2-A]PYRAZIN-1YL-BENZAMIDE COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | F. HOFFMANN-LA ROCHE AG (CH) | 2015-12-30 | — | — | WO | disclosed |
| WO-2015173181-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | F. HOFFMANN-LA ROCHE AG (CH) | 2015-11-19 | — | — | WO | disclosed |
| US-8318750-B2 | Organic compounds | NOVARTIS AG (NL) | 2012-11-27 | — | — | US | disclosed |
| US-8318750-B2 | Organic compounds | NOVARTIS AG (NL) | 2012-11-27 | — | — | US | disclosed |
| US-8258141-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-09-04 | — | — | US | disclosed |
| US-20090093633-A1 | Organic Compounds | NOVARTIS AG | 2009-04-09 | — | — | US | disclosed |
| US-20090093633-A1 | Organic Compounds | NOVARTIS AG | 2009-04-09 | — | — | US | disclosed |
| EP-1841768-B1 | PURINE DERIVATIVES ACTING AS A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2008-11-12 | — | — | EP | disclosed |
| US-20080242683-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-10-02 | — | — | US | disclosed |
| US-20080242683-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-10-02 | — | — | US | disclosed |
| US-20080207648-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-08-28 | — | — | US | disclosed |
| US-20080207648-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-08-28 | — | — | US | disclosed |
| WO-2007121920-A2 | PURINE DERIVATIVES FOR USE AS ADENOSIN A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2007-11-01 | — | — | WO | disclosed |
| WO-2007121918-A2 | USE OF 2-(PURIN-9-YL)-TETRAHYDOFURAN-3,4-DIOL DERIVATIVES AS ADENOSINE A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2007-11-01 | — | — | WO | disclosed |
| WO-2006028290-A1 | 2-MORPHOLINO-4-PYRIMIDONE COMPOUND | MITSUBISHI PHARMA CORPORATION (JP) | 2006-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242683-A1 | Organic Compounds | ADORA2A, ADORA3, ADORA1 | ALDH1A1 387/4885L3MBTL3 3112/4885L3MBTL1 3197/4885 |
| US-20090093633-A1 | Organic Compounds | ADORA2A, ADORA3, ADORA1 | ALDH1A1 478/4885L3MBTL3 4737/4885L3MBTL1 4781/4885 |
| US-20230117631-A1 | HPK1 ANTAGONISTS AND USES THEREOF | PDXK, HIPK1, PCK1 | ALDH1A1 4740/4885L3MBTL3 1663/4885L3MBTL1 1271/4885 |
| US-20180194781-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | SMN1; SMN2, PYGM, CPT1B | ALDH1A1 770/4885L3MBTL3 4141/4885L3MBTL1 3623/4885 |
| US-20080207648-A1 | Organic Compounds | ADORA2A, ADORA1, ADORA3 | ALDH1A1 201/4885L3MBTL3 4518/4885L3MBTL1 4436/4885 |
| US-10208067-B2 | Compounds for treating spinal muscular atrophy | SMN1; SMN2, PYGM, CPT1B | ALDH1A1 770/4885L3MBTL3 4141/4885L3MBTL1 3623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.